van Os J L, van Laar P H, Oldenkamp E P, Verschoor J S
Vet Q. 1981 Jan;3(1):46-56. doi: 10.1080/01652176.1981.9693795.
The incidence, size and location of mammary nodules were established in 10 practices in The Netherlands by the clinical examination of bitches in which oestrus was controlled with proligestone (P), 331 animals, or medroxyprogesterone acetate (MAP), 341 animals and in 339 animals never medicated with such compounds. In comparison with the unmedicated control and the P-medicated animals of comparable age the incidence of mammary nodules of all sizes was significantly increased in the MAP-medicated animals. There was no significant difference in nodule incidence between the P-medicated animals and the control animals. Based on the assumption that nodules above a certain size are most likely tumours, these results indicate that oestrus control with MAP stimulates tumour development even in animals medicated for less than four years. The practical value of the reported differences, especially in relation to the subsequent requirement for surgical removal of tumours in bitches, medicated for oestrus control, is discussed.
通过对荷兰10家诊所的母犬进行临床检查，确定了乳腺结节的发病率、大小和位置。这些母犬中，331只使用普罗孕酮（P）控制发情，341只使用醋酸甲羟孕酮（MAP）控制发情，另有339只从未使用过此类化合物。与未用药的对照组以及年龄相仿的使用P的动物相比，使用MAP的动物中各种大小乳腺结节的发病率显著增加。使用P的动物和对照动物之间的结节发病率没有显著差异。基于某种大小以上的结节最有可能是肿瘤这一假设，这些结果表明，即使在用药不到四年的动物中，使用MAP控制发情也会刺激肿瘤发展。文中讨论了所报告差异的实际价值，特别是与随后对控制发情用药的母犬进行肿瘤手术切除的需求相关的价值。
